Description: Hitgen focuses on the development of new drugs and is committed to creating the world's best quality DNA Encoded Library with independent intellectual property rights as a "new engine" for the creation of new drugs.
DNA encoded compounds
novel drug/target complex structures for FBDD/SBDD
HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platform